A comparison of methods for treatment selection in seamless phase II/III clinical trials incorporating information on short-term endpoints

In an adaptive seamless phase II/III clinical trial interim analysis data are used for treatment selection, enabling resources to be focussed on comparison of more effective treatment(s) with a control. In this paper we compare two methods recently proposed to enable use of short-term endpoint data for decision-making at the interim analysis. The comparison focusses on the power and the probability of correctly identifying the most promising treatment. We show that the choice of method depends on how well short-term data predict the best treatment, which may be measured by the correlation between treatment effects on short-term and long-term endpoints

Designing Digital Content to Support Science Journalism

Journalists need to become more effective at communicating science and countering post-truth activities that seek to undermine scientific processes and evidence. Digital support for journalists when investigating and writing about sciencerelated topics is one means of improving this science communication. However, little bespoke digital support is available. This paper reports the research and development of one new form of such digital support. During a participatory design process, experienced science journalists and other professionals were interviewed about their challenges experienced and understanding of good practices in science journalism. These challenges and good practices informed the development of a prototype of a new form of digital tool that was evaluated by journalists without specialist science training. A new version of the prototype, called INQUEST, was implemented to automate some parts of good practices in order to augment journalists’ capabilities. These practices included the retrieval of science information from diverse sources, targeting different science audiences, and providing different forms of guidance for explaining science to the target audience. This prototype is presented, and an early evaluation of it is reported

Adaptive clinical trials incorporating treatment selection and evaluation: methodology and application in progressive multiple sclerosis

In progressive multiple sclerosis (MS) irreversible disability often takes many years to accumulate as a result prolonged trials are required to assess the benefits of therapies. There is a need to understand the relationship between short-term outcome measures such as MRI endpoints and long-term clinical outcomes in progression to determine the evolution of the disease early on. Thus, the common phase I-II-III paradigm for clinical trial design with separate trials for each phase may not be appropriate